Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Committee Will Hear Device Concerns With Physician Payment Bill

This article was originally published in The Gray Sheet

Executive Summary

The Senate Special Committee on Aging plans to hold a hearing in the coming months on a bill that would require device and drug makers to disclose financial relationships with physicians

You may also be interested in...



Sunshine Nationwide: Fed Disclosure Law Meets Some, Not All, Industry Goals

Device industry representatives say they are happy that the new federal mandate for publicly disclosing payments to physicians includes some pre-emptive authority over states, but they hope to convince lawmakers to strengthen that authority before the new rules take effect

Sunshine Nationwide: Fed Disclosure Law Meets Some, Not All, Industry Goals

Device industry representatives say they are happy that the new federal mandate for publicly disclosing payments to physicians includes some pre-emptive authority over states, but they hope to convince lawmakers to strengthen that authority before the new rules take effect

Sens. Grassley, Kohl Retool Physician Payment Bill To Defuse Opposition

Senate lawmakers redrafted pending legislation that would require device and drug companies to publicly disclose financial relationships with doctors in response to steady lobbying by industry

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel